Outcome measure | Evidence | Implications |
---|---|---|
Patient-oriented evidence | ||
Safety and tolerability | Clear | Nilotinib is well tolerated |
Disease-oriented evidence | ||
Cytogenetic response | Substantial | Nilotinib produces major cytogenetic response in 31% (accelerated phase), 40% (blastic phase) and 57% (chronic phase) of patients resistant or intolerant to imatinib. 100% complete response has been achieved in newly diagnosed patients |
Hematologic response | Substantial | Nilotinib produces complete hematologic response in 11% (blastic phase), 26% (accelerated phase), and 77% (chronic phase) of patients resistant or intolerant to imatinib |